---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-048942"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:06:03.318039+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics prices $40M pre-funded warrant offering; lead investor Coastlands Capital

## Summary
- Pre-funded warrants to purchase 74,780,300 common shares at $0.5349/warrant; exercise price $0.0001/share.
- Gross proceeds ~$40M; net proceeds ~$37.1M after underwriting discounts and offering expenses.
- Offering led by Coastlands Capital with participation from Gilead, OrbiMed, Perceptive Advisors.
- Expected closing date February 13, 2026; net proceeds for product development and general corporate purposes.
- Pre-funded warrants immediately exercisable; beneficial ownership capped at 4.99% (holder can elect up to 19.99%).

## SEC filing metadata
- accession: 0001193125-26-048942
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526048942/0001193125-26-048942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526048942/d85184d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-048942
- JSON: https://secwatch.observer/filing/0001193125-26-048942.json
- Plain text: https://secwatch.observer/filing/0001193125-26-048942.txt

## Key facts
- Material Agreements
  Xilio Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC valued at approximately $37.1 million (effective 2026-02-11).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Leerink Partners LLC
  - Value: approximately $37.1 million
  - Effective: 2026-02-11
  source text: On February 11, 2026, Xilio Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the underwriter named therein (the “Underwriter”), relating to an underwritten offering (the “Offering”) of pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 74,780,300 shares of common stock (the “Warrant Shares”) at a price to investors of $0.5349 per Pre-Funded Warrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000119312526048942/0001193125-26-048942-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.